ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Clinical Outcomes of Solid Organ Transplant (SOT) Patients with Epstein-Barr Virus-Driven (EBV+) Post-Transplant Lymphoproliferative Disease (PTLD) Who Fail Rituximab Plus Chemotherapy: A Multinational, Retrospective Chart Review Study

V. Dharnidharka1, D. Thirumalai2, U. Jaeger3, W. Zhao2, D. Dierickx4, P. Xun2, P. Minga5, A. Sawas6, N. Sadetsky7, P. Chauvet8, E. Sundaram9, A. Barlev7, H. Zimmermann10, R. U. Trappe10

1Washington University School of Medicine/St Louis Children’s Hospital, St Louis, MO, 2Atara Biotherapeutics, Thousand Oaks, CA, 3Medical University of Vienna, Vienna, Austria, 4Universitair Ziekenhuis Leuven, Leuven, Belgium, 5Niguarda Ca’ Granda Hospital, Milan, Italy, 6Herbert Irving Comprehensive Cancer Center, Department of Medicine, CUMC, New York, NY, 7Atara Biotherapeutics, South San Francisco, CA, 8Service des Maladies du Sang, CHU Lille, Lille, France, 9Nashville Biosciences, Nashville, TN, 10DIAKO Bremen, Bremen, Germany

Meeting: 2022 American Transplant Congress

Abstract number: 60

Keywords: Epstein-Barr virus (EBV), Outcome, Post-transplant lymphoproliferative disorder (PTLD), Survival

Topic: Clinical Science » Infection Disease » 28 - PTLD: All Topics

Session Information

Session Name: PTLD and Malignancies

Session Type: Rapid Fire Oral Abstract

Date: Sunday, June 5, 2022

Session Time: 3:30pm-5:00pm

 Presentation Time: 3:40pm-3:50pm

Location: Hynes Room 309

*Purpose: EBV+ PTLD patients (pts) following SOT who fail rituximab + chemotherapy (CT) have poor outcomes with limited treatment options. Published data on clinical outcomes of these pts remain limited and not well documented.

*Methods: We conducted a large multinational, multicenter, retrospective chart review study of pts with EBV+ PTLD following allogeneic hematopoietic cell transplantation or SOT who received rituximab or rituximab + CT between Jan 2000‒Dec 2018 and were refractory (failed to achieve CR or PR) or relapsed at any point after such therapy. Data were collected from 29 centers across North America and the European Union. This analysis includes pts with EBV+ PTLD following SOT who were refractory/relapsed to rituximab + CT. Kaplan-Meier method was utilized to estimate the overall survival (OS).

*Results: A total of 86 pts were included in the analysis; 75.6% were refractory while 24.4% relapsed after initial response of CR or PR to rituximab + CT. Median age at PTLD diagnosis was 43 years (range 1‒78) and median time to PTLD onset from transplant was 1.7 years (range 0.1‒27.9). PTLD histological subtypes were 76.7% monomorphic, 20.9% polymorphic, and 2.3% early lesions. Overall, 73.3% of pts died. Causes of death comprised 65.1% PTLD, 15.9% treatment-related mortality, 3.2% organ rejection/failure, 11.1% other causes, and 4.8% unknown. Median OS was 4.1 months (95% CI: 1.9‒8.5) from the date when pts became relapsed/refractory to rituximab + CT (Fig).

*Conclusions: Prognosis for pts with EBV+ PTLD following SOT who fail rituximab + CT remains poor with an estimated median OS of about 4 months and a majority of pts dying from PTLD and related treatment. There remains a significant unmet medical need for effective and well-tolerated therapies.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Dharnidharka V, Thirumalai D, Jaeger U, Zhao W, Dierickx D, Xun P, Minga P, Sawas A, Sadetsky N, Chauvet P, Sundaram E, Barlev A, Zimmermann H, Trappe RU. Clinical Outcomes of Solid Organ Transplant (SOT) Patients with Epstein-Barr Virus-Driven (EBV+) Post-Transplant Lymphoproliferative Disease (PTLD) Who Fail Rituximab Plus Chemotherapy: A Multinational, Retrospective Chart Review Study [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/clinical-outcomes-of-solid-organ-transplant-sot-patients-with-epstein-barr-virus-driven-ebv-post-transplant-lymphoproliferative-disease-ptld-who-fail-rituximab-plus-chemotherapy-a-multinationa/. Accessed May 9, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences